Design, synthesis, and evaluation of novel 5-aminolevulinic acid and 3-hydroxypyridinone conjugates for enhanced photodynamic therapy in triple-negative breast cancer.
The novel 5-ALA-HPO conjugates show promise in enhancing photodynamic therapy efficacy in TNBC cells, but clinical implications are yet to be determined.
Where it sits
this study against the rest of the dsip corpusSummary and findings
The study synthesized and evaluated 28 novel prodrug conjugates of 5-aminolevulinic acid and 3-hydroxypyridinone for photodynamic therapy in triple-negative breast cancer cells. The R-configuration conjugates, 13a and 13d, showed enhanced phototoxicity with IC50 values of 51.16 ± 1.93 μM and 49.65 ± 2.50 μM, respectively, compared to >100 μM for 5-ALA. These conjugates also increased intracellular PpIX fluorescence nearly 4-fold over 5-ALA.
Abstract
Triple-negative breast cancer (TNBC) is a highly aggressive malignancy lacking effective targeted therapies. While 5-Aminolevulinic acid (5-ALA) is an FDA-approved prodrug for photodynamic therapy (PDT), its clinical efficacy against TNBC is severely restricted by poor lipophilicity and the rapid metabolic clearance of its active photosensitizer, protoporphyrin IX (PpIX), into heme. To overcome these limitations, we designed and synthesized 28 novel prodrug conjugates by covalently linking 5-ALA with the iron chelator 3-hydroxypyridinone (HPO) via an ester bond, exploring both R and S stereochemical configurations. Biological evaluations revealed that these conjugates possessed significantly improved lipophilicity and negligible dark toxicity, while exhibiting significantly enhanced phototoxicity to free 5-ALA. Notably, the R-configuration conjugates 13a and 13d emerged as the most potent candidates against MDA-MB-231 TNBC cells, demonstrating IC<sub>50</sub> values of 51.16 ± 1.93 μM and 49.65 ± 2.50 μM, respectively (vs. >100 μM for 5-ALA). Mechanistic studies suggested that these conjugates induced nearly 4-fold higher intracellular PpIX fluorescence than 5-ALA, which is hypothesized to correlate with HPO-mediated labile iron chelation and subsequent preservation of the intracellular PpIX pool against ferrochelatase-mediated clearance. These findings highlight the promise of 5-ALA-HPO conjugates as synergistic, dual-action photosensitizers for advancing PDT in aggressive TNBC models in vitro.
Background
Triple-negative breast cancer (TNBC) is an aggressive form of cancer that lacks effective targeted therapies. 5-Aminolevulinic acid (5-ALA) is used in photodynamic therapy (PDT) but is limited by poor lipophilicity and rapid metabolic clearance. This study aims to enhance the efficacy of 5-ALA in TNBC by improving its pharmacokinetic properties through novel conjugates.
Methods
The study involved the design and synthesis of 28 prodrug conjugates by linking 5-ALA with 3-hydroxypyridinone (HPO) via an ester bond. Both R and S stereochemical configurations were explored. The biological evaluation was conducted on MDA-MB-231 TNBC cells to assess lipophilicity, dark toxicity, and phototoxicity.
Results
The R-configuration conjugates 13a and 13d demonstrated significantly enhanced phototoxicity with IC50 values of 51.16 ± 1.93 μM and 49.65 ± 2.50 μM, respectively, compared to >100 μM for 5-ALA. These conjugates also induced nearly 4-fold higher intracellular PpIX fluorescence, suggesting improved retention and efficacy.
Interpretation
The findings suggest that the novel 5-ALA-HPO conjugates could potentially improve the efficacy of PDT in TNBC by enhancing intracellular PpIX retention. However, the clinical significance remains uncertain due to the in vitro nature of the study. Further research is needed to confirm these effects in vivo and assess clinical relevance.
Key findings
- 28 novel prodrug conjugates synthesized.
- IC50 values of 51.16 ± 1.93 μM and 49.65 ± 2.50 μM for conjugates 13a and 13d.
- Conjugates showed >100 μM IC50 for 5-ALA.
- Nearly 4-fold higher intracellular PpIX fluorescence than 5-ALA.
Limitations
- In vitro study only.
- Specific to MDA-MB-231 TNBC cell line.
- No in vivo validation.
- Short-term evaluation of effects.